Amber D. Van Laar MD

PubMed

• 20 citations
  Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
  Chadwick W. Christine, R. Mark Richardson, Amber D. Van Laar, Marin E. Thompson, Elisabeth M. Fine
  Neurology. 2021-10-14
• 11 citations
  Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials
  Aristide Merola, Noelle Kobayashi, Alberto Romagnolo, Brenton A Wright, Carlo Alberto Artusi
  Frontiers in Neurology. 2021-04-06
• 17 citations
  An Update on Gene Therapy Approaches for Parkinson's Disease: Restoration of Dopaminergic Function.
  Amber D. Van Laar, Victor S. Van Laar, Waldy San Sebastian, Aristide Merola, J. Bradley Elder
  Journal of Parkinson's Disease. 2021-01-01

Journal Articles

• Non-motor Symptoms of Parkinson Disease: Update on the Diagnosis and Treatment  
  Amber D. Van Laar, MD and Samay Jain, MD, MS, Neurologist, 7/10/2014

Abstracts/Posters

• Intraputaminal AADC gene therapy for advanced Parkinson’s disease: Interim Results of a Phase 1b
  Christine CW, Bankiewicz KS, Van Laar AD, Richardson R, Ravina B, Kells A, Boot B, Martin A, Thompson M, Larson P, European Society for Gene and Cell Therapy, XXV Anniversary Congress, Berlin, Germany, 10/2017
• Real-time MRI-guided intraputaminal AADC gene therapy for advanced Parkinson’s disease.
  Richardson R, Christine CW, Bankiewicz KS, Van Laar AD, Ravina B, Kells A, Boot B, Larson P, World Society for Stereotactic and Functional Neurosurgery Quadrennial Meeting, Berlin, Germany, 6/2017
• Intraputaminal AADC gene therapy for advanced Parkinson’s disease: Interim Results of a Phase 1b Trial.
  Christine CW, Bankiewicz KS, Van Laar AD, Richardson R, Ravina B, Kells A, Boot B, Martin A, Thompson M, Larson P., American Academy of Neurology 69th Annual Meeting, Boston, MA, 4/2017
• . A novel, progressive, endogenous synucleinopathy model of Parkinson disease in rats.
  Van Laar AD, Webb KR, Burton EA, Greenamyre JT, Society for Neuroscience, San Diego,CA, 11/2016
• A novel, endogenous synucleinopathy model of Parkinson disease in rats
  Van Laar AD, Webb KR, Burton EA, Greenamyre JT., 30th Annual Parkinson Study Group, Portland, OR, 9/2016
• AAV2-AADC Gene Therapy for Parkinson’s Disease: Therapeutic Potential and Surgical Coverage of the Putamen using MRI-Guided Convective Delivery.
  Bankiewick KS, Christine CW, Thompson M, Bringas J, Ravina B, Richardson M, Van Laar A, and Larson P., Michael J Fox Foundation Therapeutics Conference, New York, NY, 2016
• Frontotemporal dementia associated with a Valosin-Containing Protein mutation: report of three families
  Spina S, Van Laar AD, Murrell J, de Courten-Myers G, Hamilton R, Farlow M, Quinlan J, Ghetti B, DeKosky S., AAN Annual Meeting Abstract, 3/2008
• Selenium supplementation and dopamine induced toxicity.
  Cavanaugh AD & Hastings TG, Society for Neuroscience, Washington, DC, 2005
• Alpha-synuclein regulates dopamine synthesis at multiple sites.
  Tehranian R, Peng X, Cavanaugh AD, Stefanis L, Hastings TG, Perez RG, Society for Neuroscience, Washington, DC, 2004
• Protective effects of dietary creatine and nicotinamide against dopamine induced neurotoxicity.
  Cavanaugh AD, Becker T, Thompson T, Jackson B, and Hastings TG, Society for Neuroscience, 1/1/2003
• Join now to see all